Efficacy and Tolerability of Tolterodine Extended Release in Male and Female Patients with Overactive Bladder

Abstract

ObjectivesTo evaluate the efficacy and tolerability of tolterodine extended release (ER) in men and women with overactive bladder (OAB). MethodsWe analyzed data from two 12-wk, placebo-controlled trials of tolterodine ER (4mg QD). Patients completed 7-d bladder diaries and rated the urgency sensation associated with each micturition on a 5-point urgency rating scale. Micturitions were categorized by urgency rating: total (1–5), non-OAB (1–2), OAB (3–5), or severe OAB (4–5). Changes in micturitions during 24-h, daytime, and nocturnal intervals were assessed. ResultsAt baseline, 73% (547 of 745) of men and 57% (539 of 953) of women were continent. By week 12, tolterodine ER (n=848) reduced OAB and severe OAB micturitions during 24-h, daytime, and nocturnal intervals in both sexes compared with placebo (n=850). Adverse event rates were low and similar across treatment and gender. ConclusionsIn men and women with OAB, tolterodine ER reduced OAB and severe OAB micturitions, and was well tolerated.